High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review
Open Access
- 1 June 2021
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 97, 102171
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumorsInvestigational New Drugs, 2012
- Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancerBritish Journal of Cancer, 2011
- Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer ModelingScience Translational Medicine, 2011
- High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular ResponsesJournal of Clinical Oncology, 2009
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Targeting cancer with small molecule kinase inhibitorsNature Reviews Cancer, 2009
- KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursEuropean Journal of Cancer, 2006
- Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With CancerJournal of Clinical Oncology, 2006
- Randomized Phase II Trial of the Clinical and Biological Effects of Two Dose Levels of Gefitinib in Patients With Recurrent Colorectal AdenocarcinomaJournal of Clinical Oncology, 2005
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004